Technology name
Last update: Feb 2025Extruded Polymer Device (EXPD)
Developer(s)
Type of technology
Polymeric implant
Administration route
Subcutaneous
Development state and regulatory approval
Non-nucleoside reverse transcriptase inhibitors (NNRTI), Unspecified NNRTI
Pre-clinical
Not provided
Description
Reservoir implant releasing one or more active pharmaceutical agents with constant release. Implant retrievable during drug release and biodegradable after drug depletion. The implant is 2.5mm x 40 mm. One or two implants can be used simultaneously.
Developer(s)
RTI International
Technology highlight
Bioabsorbable subcutaneous long-acting implant platform with more than 6 month duration; compatible with several potent antiretroviral classes and hormones for HIV and/or contraception; removable for up to at least 6 months (but not required); scalable manufacturing processes.
Illustration(s)
Technology main components
The implant is extruded from a GMP grade polycaprolactone (PCL) used for medical device applications and medical-grade excipients that are generally recognized as safe (GRAS) for subcutaneous administration.
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
APIs compatibility profile
Not provided
Not provided
Not provided
To be provided
2 different APIs : Two or more active pharmaceutical ingredients can be delivered
Not provided
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
The implant can be delivered through existing, commercially available trocars
Additional features
- Biodegradable
- Drug-eluting
- Removable
- Single-use
- Reservoir-type
Constant release for at least 6 months.
Not provided
Not provided
Not provided
Therapeutic area(s)
- Contraception
- Multipurpose technology : "HIV PrEP and contraception"
- Other(s) : "Breast cancer (treatment and prevention)"
- HIV
- Pre-Exposure Prophylaxis (PrEP)
- Treatment
Potential associated API(s)
- Tenofovir alafenamide (TAF)
- Non-nucleoside reverse transcriptase inhibitors (NNRTI) , Unspecified NNRTI
- Integrase inhibitors (INSTIs)
- Etonogestrel (ENG)
- Selective estrogen receptor modulators (SERMs)
- Islatravir (ISL)
- Levonorgestrel (LNG)
- Islatravir (ISL) , Levonorgestrel (LNG)
Use of technology
- Administered by a nurse
- Administered by a specialty health worker
Every 6 months, Yearly
Targeted user groups
- Adults
- All
- Male
- Female
- Cisgender female
- Cisgender male
- Transgender female
- Transgender male
- Intersex
- Gender non-binary
Unspecified
Unspecified
Unspecified
To be further investigated
NRTI ; Antiviral
Pre-clinical
Not provided
Not provided
Not provided
Not provided
None
Non-nucleoside reverse transcriptase inhibitors (NNRTI) , Unspecified NNRTI
Antiviral
Pre-clinical
Not provided
Not provided
Not provided
Not provided
Not provided
Integrase inhibitors (INSTIs)
INSTIs, Antiretroviral
Pre-clinical
Not provided
Not provided
Not provided
Not provided
Not provided
Etonogestrel (ENG)
Hormones
Pre-clinical
Not provided
Not provided
Not provided
1 year
None
Selective estrogen receptor modulators (SERMs)
Estrogen receptor
Pre-clinical
Not provided
Not provided
Not provided
Not provided
Not provided
NRTI; Antiviral
Pre-clinical
Not provided
Not provided
Not provided
6 months
None
Levonorgestrel (LNG)
Hormones
Pre-clinical
Not provided
Not provided
Not provided
Not provided
None
Islatravir (ISL) , Levonorgestrel (LNG)
antiviral (NRTI) + contraceptive hormone
Pre-clinical
Not provided
Not provided
Not provided
6 months to 1 year
None
